Abivax: positive results after two years of maintenance

(CercleFinance.com) - On Thursday, Abivax announced positive results from an interim analysis of its lead drug candidate for the treatment of ulcerative colitis (UC) after two years of maintenance.


According to the data, patients receiving a reduced dose of 25 mg of its small molecule obefazimod once daily maintained clinical remission at 48 and 96 weeks.

In this maintenance study, patients who had completed phase 2a (four years) or phase 2b (two years) studies - where they had received 50 mg obefazimod once daily - were able to continue treatment with a reduced dose of 25 mg daily for up to five additional years.

The results observed with a lower dose are particularly encouraging, as they offer clinicians the possibility of reducing the dose once remission has been achieved," says Dr Marla Dubinsky, co-director of the Susan and Leonard Feinstein IBD Clinical Center at the Icahn School of Medicine, Mount Sinai, New York.

Abivax emphasizes that the efficacy and tolerability of obefazimod have been demonstrated for up to six years of treatment.

Following these announcements, the biotech company's shares were up by more than 1% late Thursday morning in Paris.

Encouraging Phase 2 results in UC patients led to the launch of a pivotal Phase 3 clinical program worldwide in 2022.

The launch of a phase 2b clinical trial in Crohn's disease is expected in Q3 2024.

Obefazimod is an orally administered small molecule shown to potentially enhance the expression of a single microRNA.


Copyright (c) 2024 CercleFinance.com. All rights reserved.